Zespół Lennoxa-Gastauta: badanie fazy III leku carisbamate
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Badania kliniczne, które rekrutują lub wkrótce zaczną rekrutację w ośrodkach w mieście Warszawa. Najwięcej badań dotyczy: nowotwór, choroba sercowo-naczyniowa, choroba układu pokarmowego, choroba metaboliczna.
1152 badania: 1050 rekrutuje, 102 wkrótce zaczną.
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
AutoInflammatory Disease Alliance Registry (AIDA)
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis…
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Inappropriate Sinus Tachycardia Registry
A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
Phase 1 Study of MK-1084 in KRAS mutant advanced solid tumors
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy
Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
European Disease Registry on Retinopathy of Prematurity (ROP)
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients with Metastatic Colorectal Cancer (INTRINSIC)
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated…
Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 17 listopada 2026.